Anthera Pharmaceuticals, Inc. (ANTH)

Anthera Pharmaceuticals, Inc. (ANTH) Healthcare & Pipeline Overview

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for unmet medical needs. With Sollpura in Phase III for exocrine pancreatic insufficiency and Blisibimod in Phase II for B-cell mediated autoimmune diseases, the company aims to address specific therapeutic gaps, operating within the specialized biotechnology sector from its Houston headquarters.

What Is the Investment Thesis for ANTH?

Anthera Pharmaceuticals, Inc. is positioned as a development-stage biopharmaceutical company with a pipeline focused on addressing unmet medical needs. The investment thesis centers on the potential for its lead investigational therapies, Sollpura and Blisibimod, to successfully navigate clinical trials and achieve regulatory approval. Sollpura, currently in Phase III for exocrine pancreatic insufficiency, represents a significant value driver; successful completion of this pivotal trial and subsequent commercialization could unlock substantial market potential, particularly given its non-porcine formulation as a differentiator. Blisibimod, in Phase II for B-cell mediated autoimmune diseases like IgA nephropathy, offers further upside if it demonstrates efficacy and safety in later-stage trials. The company's existing license agreements with Amgen, Inc., and Eli Lilly and Company also provide a foundation for potential future collaborations or revenue streams. However, the company's extremely small market capitalization of 26K, its OTC Other tier listing, and the inherent high-risk nature of clinical-stage biotechnology development, including potential trial failures, regulatory setbacks, and funding challenges, represent significant risk factors that must be carefully considered by investors.

Based on FMP financials and quantitative analysis

ANTH Key Highlights

• Market Capitalization: $0.00B, indicating an extremely small valuation.
• Beta: -123.12, suggesting an inverse and highly volatile relationship with the broader market, which is atypical and warrants close scrutiny.
• Employee Count: Operates with a lean team of 21 employees, reflecting its development-stage focus.
• Dividend Policy: Does not currently pay a dividend, consistent with a growth-oriented, pre-revenue biopharmaceutical company.
• Clinical Pipeline Progress: Sollpura is in Phase III for exocrine pancreatic insufficiency, while Blisibimod is in Phase II for B-cell mediated autoimmune diseases.

Who Are ANTH's Competitors?

ANTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANTH's Key Strengths?

• Advanced clinical pipeline with Sollpura in Phase III and Blisibimod in Phase II, targeting significant unmet medical needs.
• Sollpura's non-porcine formulation offers a potential differentiator in the pancreatic enzyme replacement therapy market.
• Strategic license agreements with established pharmaceutical companies, Amgen and Eli Lilly, provide external validation and potential resource access.
• Focused R&D approach on specific therapeutic areas, allowing for specialized expertise.

What Are ANTH's Weaknesses?

• Extremely small market capitalization ($0.00B) and low stock price ($0.0001), indicating significant financial distress.
• OTC Other tier listing, which typically implies lower transparency, liquidity, and increased risk for investors.
• High beta (-123.12) suggests extreme volatility and an unusual inverse correlation, indicating unpredictable price movements.
• Limited operational scale with only 21 employees, potentially straining resources for multiple advanced clinical programs.

What Could Drive ANTH Stock Higher?

• **Upcoming:** Announcement of Phase III clinical trial results for Sollpura in exocrine pancreatic insufficiency.
• **Upcoming:** Progress updates or data readouts from the Phase II clinical trial for Blisibimod in B-cell mediated autoimmune diseases.
• **Upcoming:** Potential new or expanded license agreements with pharmaceutical partners based on pipeline advancement.
• **Ongoing:** Any corporate restructuring efforts or financing initiatives aimed at improving financial stability.

What Are the Key Risks for ANTH?

• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• **Ongoing:** Significant financial distress, evidenced by an extremely small market capitalization and low stock price, posing a risk of delisting or business cessation.
• **Potential:** Failure of Sollpura's Phase III clinical trial, which would severely impact the company's lead asset and future prospects.
• **Potential:** Inability to secure additional funding required to complete ongoing clinical trials or commercialize approved therapies.
• **Ongoing:** High regulatory risk inherent in biopharmaceutical development, including potential delays or outright rejection of drug candidates.
• **Potential:** Intense competition from larger, better-funded pharmaceutical companies developing similar or alternative treatments.

What Are the Growth Opportunities for ANTH?

• **Successful Commercialization of Sollpura:** The most immediate and significant growth opportunity for Anthera Pharmaceuticals lies in the successful completion of Phase III clinical trials for Sollpura, its non-porcine pancreatic enzyme replacement therapy for exocrine pancreatic insufficiency (EPI). The global market for pancreatic enzyme replacement therapy (PERT) is substantial, driven by conditions like cystic fibrosis and chronic pancreatitis. A successful trial outcome, followed by regulatory approval and commercial launch, could position Sollpura as a differentiated alternative, potentially capturing a significant share of this market, which is projected to grow steadily. The non-porcine aspect could appeal to patient segments with dietary restrictions or preferences, offering a unique selling proposition and a clear path to revenue generation within the next few years, assuming a positive trial and approval timeline.
• **Advancement and Approval of Blisibimod:** The progression of Blisibimod through Phase II clinical trials for B-cell mediated autoimmune diseases, including IgA nephropathy, represents another crucial growth avenue. IgA nephropathy is a serious chronic kidney disease with limited specific treatment options, indicating a significant unmet medical need. The global market for autoimmune disease treatments is vast and continuously expanding, with new targeted therapies commanding premium pricing. Positive results in Phase II and subsequent Phase III trials could lead to a valuable asset that addresses a critical gap in treatment paradigms for IgA nephropathy patients. This could open up a new therapeutic franchise for Anthera, diversifying its pipeline and revenue potential over a longer-term horizon, likely 5-7 years for full commercialization.
• **Leveraging Existing License Agreements:** Anthera's license agreements with Amgen, Inc., and Eli Lilly and Company present a strategic growth opportunity. While the specifics of these agreements are not detailed, such partnerships often involve milestone payments, royalties on future sales, or collaborative development efforts. These agreements could provide non-dilutive funding, access to broader research and development capabilities, or a pathway to co-commercialization. Strengthening or expanding these relationships, or forming new ones based on the progress of their pipeline, could accelerate development, de-risk projects, and provide additional revenue streams without requiring Anthera to build out extensive commercial infrastructure independently. This could manifest as early as the next 2-3 years depending on milestones.
• **Expansion into New Therapeutic Indications:** The underlying mechanisms of action for both Sollpura (enzyme replacement) and Blisibimod (B-cell modulation) could potentially be applicable to other related conditions beyond their current primary indications. For example, if Blisibimod proves effective in IgA nephropathy, its mechanism might be explored for other B-cell mediated autoimmune disorders, thereby expanding its addressable market. Similarly, Sollpura's non-porcine enzyme technology could potentially be adapted for other digestive enzyme deficiencies. This strategic expansion, contingent on initial success, would broaden the company's therapeutic reach and market opportunities, leveraging its existing R&D investments. This would be a mid-to-long-term opportunity, likely requiring additional preclinical and clinical work over 5-10 years.
• **Strategic Partnerships and Acquisitions:** Given its small size and focus on specific drug candidates, Anthera Pharmaceuticals could become an attractive target for strategic partnerships, co-development agreements, or even acquisition by larger pharmaceutical companies seeking to bolster their pipeline in gastroenterology or autoimmune diseases. A successful Phase III readout for Sollpura or strong Phase II data for Blisibimod would significantly enhance Anthera's appeal. Such a transaction could provide substantial capital, integrate Anthera's assets into a larger commercial infrastructure, and potentially offer a premium valuation for shareholders. This opportunity is highly dependent on clinical success and market conditions, but could materialize within the next 3-5 years following key data readouts.

What Opportunities Does ANTH Have?

• Successful completion of Sollpura's Phase III trial and subsequent regulatory approval could lead to significant revenue generation.
• Positive Phase II results for Blisibimod could attract further investment or partnership opportunities for its development.
• Potential for expanded indications for existing drug candidates, broadening market reach and revenue streams.
• Strategic acquisition by a larger pharmaceutical company seeking to enhance its pipeline in gastroenterology or autoimmune diseases.

What Threats Does ANTH Face?

• High risk of clinical trial failures, which would severely impact the company's valuation and future prospects.
• Potential for regulatory setbacks or delays in gaining approval for its drug candidates.
• Intense competition from larger pharmaceutical companies with greater financial and R&D resources.
• Ongoing financial instability and the high risk of delisting from the OTC market due to non-compliance or lack of funding.

What Are ANTH's Competitive Advantages?

• **Proprietary Drug Candidates:** Development of unique investigational therapies like Sollpura (non-porcine PERT) and Blisibimod (B-cell modulator) in specific therapeutic areas.
• **Clinical Trial Progress:** Advancement of Sollpura to Phase III and Blisibimod to Phase II represents significant investment and progress, creating a lead time advantage over potential new entrants.
• **Targeted Unmet Needs:** Focus on specific diseases with high unmet medical needs, potentially leading to faster regulatory pathways and strong market positioning upon approval.
• **Strategic License Agreements:** Existing partnerships with established pharmaceutical companies like Amgen and Eli Lilly provide validation and potential access to resources or market reach.

What Does ANTH Do?

Anthera Pharmaceuticals, Inc., founded in 2004 and based in Houston, Texas, operates as a biopharmaceutical company dedicated to the development and commercialization of innovative medicines targeting patients with significant unmet medical needs. The company's strategic focus is on advancing its pipeline through clinical trials to bring novel therapies to market. A cornerstone of its development efforts is Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy. This candidate is currently undergoing Phase III clinical trials, aiming to provide a new treatment option for individuals suffering from exocrine pancreatic insufficiency (EPI), a condition characterized by the inability to properly digest food due to a lack of digestive enzymes produced by the pancreas. The successful development and approval of Sollpura could address a critical demand within the gastroenterology therapeutic area, offering an alternative to existing porcine-derived enzyme therapies. In addition to Sollpura, Anthera Pharmaceuticals is also progressing Blisibimod, a drug candidate in Phase II clinical trials. Blisibimod is being developed for the treatment of B-cell mediated autoimmune diseases, specifically including immunoglobulin A nephropathy (IgA nephropathy). IgA nephropathy is a chronic kidney disease that occurs when immunoglobulin A (IgA) deposits build up in the kidneys, leading to inflammation and damage. The development of Blisibimod signifies the company's commitment to addressing complex autoimmune conditions where current treatment options may be limited or insufficient. The company's operational model is further bolstered by strategic license agreements with established pharmaceutical giants, Amgen, Inc., and Eli Lilly and Company. These agreements underscore Anthera's collaborative approach to drug development and potentially provide access to broader resources or expertise. Despite its small operational footprint, with 21 employees, Anthera Pharmaceuticals positions itself within the highly specialized biotechnology sector, aiming to carve out market niches by focusing on therapies for specific, often rare, diseases. The company's current market capitalization is noted as extremely small, and it trades on the OTC Other tier, indicating a focus on early-stage development and the inherent risks associated with biopharmaceutical ventures.

What Products and Services Does ANTH Offer?

• Develops Sollpura, a non-porcine pancreatic enzyme replacement therapy.
• Sollpura is in Phase III clinical trials for exocrine pancreatic insufficiency (EPI).
• Develops Blisibimod, a treatment for B-cell mediated autoimmune diseases.
• Blisibimod is in Phase II clinical trials for conditions like IgA nephropathy.
• Focuses on medicines for patients with unmet medical needs.
• Engages in license agreements with larger pharmaceutical companies like Amgen, Inc., and Eli Lilly and Company.
• Conducts biopharmaceutical research and development from its Houston, Texas headquarters.

How Does ANTH Make Money?

• **Research and Development:** Invests in preclinical and clinical studies to advance drug candidates through various development phases.
• **Clinical Trials:** Conducts rigorous human trials (Phase I, II, III) to prove the safety and efficacy of its investigational therapies.
• **Licensing and Partnerships:** Secures and maintains license agreements with larger pharmaceutical companies, potentially generating milestone payments or royalties.
• **Future Commercialization:** Aims to commercialize approved therapies, either independently or through partnerships, to generate product sales revenue.

What Industry Does ANTH Operate In?

Anthera Pharmaceuticals, Inc. operates within the highly specialized and research-intensive biotechnology industry, a sub-sector of healthcare. This industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles, but also offers substantial rewards for successful drug innovation, particularly in areas of unmet medical need. The market trend favors companies developing targeted therapies for specific diseases, especially those with orphan drug potential or significant patient populations lacking effective treatments. Anthera's focus on exocrine pancreatic insufficiency with Sollpura and B-cell mediated autoimmune diseases like IgA nephropathy with Blisibimod positions it within these niche, yet critical, therapeutic areas. The competitive landscape includes both large pharmaceutical companies with extensive R&D budgets and smaller, agile biotechs vying for market share in specific disease indications. Anthera's strategy appears to be one of differentiation through novel mechanisms or formulations, such as Sollpura's non-porcine nature, aiming to address specific patient needs not fully met by existing therapies.

Who Are ANTH's Key Customers?

• **Patients with Exocrine Pancreatic Insufficiency (EPI):** Individuals requiring enzyme replacement therapy, particularly those who might benefit from a non-porcine option.
• **Patients with B-cell Mediated Autoimmune Diseases:** Specifically, those diagnosed with conditions like IgA nephropathy, seeking novel treatment options.
• **Healthcare Providers:** Physicians, specialists, and hospitals who would prescribe or administer Anthera's approved therapies.
• **Pharmaceutical Partners:** Companies like Amgen and Eli Lilly, through strategic collaborations and licensing.

F-Score 0/9Financial Health

Anthera Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ANTH Valuation & Market Position

With a 26K market cap, Anthera Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ANTH's quantitative score of 41/100 is below the peer average of 76/100.

Company Profile

Anthera Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Paul F. Truex. ANTH has traded publicly since 2010.

ANTH Financials

ANTH Latest News

ANTH Analyst Consensus

ANTH MoonshotScore

What Investors Ask About Anthera Pharmaceuticals, Inc. (ANTH) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources